PTC Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of rare diseases and cancer
The company specializes in the development of small molecules and gene therapies that target underlying genetic causes of diseases. PTC Therapeutics aims to advance its proprietary drug candidates through clinical trials, leveraging its unique expertise in RNA biology and translational medicine. By utilizing cutting-edge technology and a collaborative approach, the company strives to bring transformative treatments to patients with unmet medical needs.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQPTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PTCT.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQPTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/PTCT.
San Diego, CA -- (SBWIRE) -- 10/10/2023 -- PTC Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQPTCT) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQPTCT) for violations of the securities laws.
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of PTC Therapeutics (NASDAQPTCT) (“PTC” or the “Company”). The investigations concern whether certain of the Company’s officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of PTC’s business practices.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQPTCT) for violations of the securities laws.
